By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Juventas Therapeutics, Inc. 

10265 Carnegie Avenue

Cleveland  Ohio  44106  U.S.A.
Phone: 216-445-0830 Fax: 216-445-6514



Company News
Juventas Therapeutics, Inc. Strengthens Leadership Team By Adding Two Industry Veterans 7/24/2014 9:16:36 AM
Juventas Therapeutics, Inc. To Present At The JMP Securities 2014 Healthcare Conference On June 24 6/23/2014 8:28:11 AM
Juventas Therapeutics, Inc. Data Demonstrates Significant Structural, Clinically Meaningful Benefit In Patients With Advanced Heart Failure 5/19/2014 6:32:48 AM
Juventas Therapeutics, Inc. To Present Top-Line Interim Results From Phase 2 STOP-HF Trial In Late-Breaking Oral Presentation At European Society of Cardiology Heart Failure Congress 5/6/2014 8:19:26 AM
Juventas Therapeutics, Inc. Completes Enrollment of Phase II STOP-HF Study of JVS-100 in Patients With Symptomatic Heart Failure 10/28/2013 11:02:51 AM
Juventas Therapeutics, Inc. Hires Biotechnology Veteran Paul Resnick as Vice President of Business Development 1/28/2013 9:54:34 AM
Juventas Therapeutics, Inc. Doses First Patient in Phase II STOP-HF Trial 8/20/2012 10:52:31 AM
Juventas Therapeutics, Inc. Raises $22.2 Million Series B Financing 7/16/2012 8:04:06 AM
Juventas Therapeutics, Inc. Enrolling Patients in Phase IIa STOP-CLI Clinical Trial 5/15/2012 12:29:27 PM
BioCardia and Juventas Therapeutics, Inc. Announce Phase II Development Program of JVS-100 Delivered With the Helical Infusion System to Treat Heart Failure 3/15/2012 6:20:34 AM